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NEUTROPHILS IN PANCREATIC CANCER PROGRESSION
Paran Goel, M.S.
University of Nebraska Medical Center, 2021
Supervisor: Rakesh K. Singh, Ph.D.
ABSTRACT
Pancreatic cancer (PC) remains a challenge to modern-day cancer therapeutics,
with a dismal five-year survival rate of 10%. Due to the pancreas's location and
desmoplasia surrounding it, patients receive late diagnoses and fail to respond to
chemotherapy regimens. Tumor-promoting inflammation, one of the emerging hallmarks
of cancer, contributes to tumor cells' survival and proliferation. This inflammation is often
the result of infiltrating leukocytes and pro-inflammatory cytokines released into the tumor
microenvironment (TME).
Neutrophils, one of the most prominent immune cells in our body, play an essential
role in sustaining this smoldering inflammation observed in the TME. Previously, our
group has shown that these neutrophils are complicit in breast cancer progression and
even metastasis. With a similar rationale in mind, this study focuses on how neutrophils
invading the TME, also known as tumor-associated neutrophils (TAN's), correlate with
disease progression in pancreatic cancer. Our data demonstrated that TAN infiltration is
associated with disease progression.
Furthermore, to understand this TAN infiltration, we theorized that the TME plays
a significant role in TAN recruitment and TAN proliferation. Our previous work elucidated
TAN recruitment by showing increased expression of chemokines in the TME. We also
ii

examined TAN and tumor cell interaction in vitro and observed increased tumor cell
survival and decreased neutrophil survival. This is theoretically explained by the
increased propensity of neutrophils to undergo NETosis and form neutrophil extracellular
traps, which have also been shown to correlate with disease progression. Our data
suggested neutrophil differentiation in the TME leads to the upregulation of multiple
chemokines and, in theory, explains the high TAN infiltration observed in the TME.
Together, these data suggest the critical role of TAN and tumor cell interaction in the
TME.
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INTRODUCTION
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The War on Cancer
In 1971, U.S. President Richard Nixon announced the 'War on Cancer' by signing
the National Cancer Act. The purpose was to find a cure for cancer. Although the holy
grail of cancer therapeutics remains elusive to modern science, we have made
outstanding progress in the last 50 years of research. The mortality rate for cancer has
significantly declined, with noticeable improvements in lung, prostate, and breast
cancer71. Although rising cancer awareness worldwide plays a part in this success, the
advent of modern screening techniques for cancer detection and new cancer therapeutics
has made considerable inroads in cancer detection and treatment. However, our war on
cancer is far from over. Cancer remains the second most leading cause of death in the
United States, behind cardiovascular diseases (Center for Disease and Control
Prevention, https://www.cdc.gov/cancer/dcpc/data/index.htm).
Cancer is described as the uncontrolled growth of host cells, which can invade
other parts of our body.

Weinberg and Hanahan eloquently detailed specific

characteristics a tumor cell develop during its life cycle in their landmark article in 20001.
These characteristics, which they call hallmarks, provide a solid foundation to create new
targets for modern cancer therapeutics. Briefly, the six hallmarks of cancer were classified
as 1) sustained proliferative signaling, 2) evading growth suppressors, 3) ability to
metastasize, 4) resisting cell death, 5) enabling replicative immortality, and 6) induced
angiogenesis1. Since then, Weinberg and Hanahan have broadened their horizon and
added two additional hallmarks, 'dysregulating cellular metabolism' and 'avoiding immune
destruction' 23.
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One of the enabling characteristics of these hallmarks is tumor-promoting
inflammation23. Cancer is often considered the 'wound which never heals' and behaves
as a constant source of inflammation. This results in the recruitment of a plethora of
different immune cells into the tumor region, which further instigates inflammation,
creating a positive feedback loop. Many articles have shed light on the link between
inflammation and tumor development, particularly in the context of pancreatic cancer.
Inflammation in pancreatic cancer derives from the crosstalk between immune cells and
the tumor, which is carried out through various pro-inflammatory cytokines61.
Pancreatic Cancer
Although the future looks promising with most types of cancer, the threat of
pancreatic cancer still looms on the horizon. Despite being a relatively rare type of cancer,
accounting for only 3% of the total cases in the United States, it causes about 8% of the
total estimated deaths. In fact, by 2030, the American Cancer Society has suggested that
pancreatic cancer will be the second most leading cause of cancer-related deaths.
As the name suggests, pancreatic cancer originates from the pancreas, a vital
organ involved in digestive and endocrine functions. Most of these cancers originate from
exocrine cells (85%) and are thus called exocrine cancers. These cancers are challenging
to diagnose early, and most patients end up being diagnosed when cancer has
metastasized to various organs, such as the liver. Unfortunately, at this point, surgical
intervention is no longer a viable option. The patient must undergo chemotherapy-based
regimens, which are not very effective in the context of pancreatic cancer. The delayed
diagnosis and absence of efficacious treatment options have held the 5-year overall
survival rate of pancreatic cancer to less than 10%.
3

As is the case for most cancers, the advent of tumorigenesis in pancreatic cancer
stems from oncogenic mutations in the exocrine cells. Almost 90% of these tumors have
the KRAS oncogenic mutation, which is involved in downstream signaling pathways
enhancing survival3. Like most cancers, the p53 tumor suppressor gene is commonly
found to be mutated in pancreatic cancer4. P53 expression is frequently associated with
cell cycle arrest by blocking the G1/S checkpoint upon sensing DNA damage and
subsequently initiating apoptosis.
Chemoresistance in Pancreatic Cancer
The ability of a tumor to resist chemotherapeutic drugs is called chemoresistance
and is commonly observed in PDAC62. It is broadly defined under two categories; intrinsic
or acquired resistance5. Intrinsic resistance in pancreatic cancer is seen as the presence
of a characteristically dense stroma derived from pancreatic stellate cells that secrete
collagen, one of the building blocks of the extracellular matrix (ECM)3. This stroma acts
as a physical barrier preventing chemotherapeutic drug entry into the tumor, diminishing
the effectiveness of chemotherapy regimens. Acquired resistance or resistance that is
conferred after prolonged treatment with chemotherapeutic drugs is attained by multiple
pathways. A common pathway involves the efflux of hydrophobic drugs through the cell
membrane by utilizing ATP binding cassette transporters6. Another cancer cell trait
showing an interesting role in chemoresistance is epithelial to mesenchymal transition
(EMT), a crucial step towards metastasis in cancer7. A study published in 2015 showed
that inhibiting EMT through deletion of vital transcription factors Snail and Twist resulted
in increased sensitivity for gemcitabine treatment in their Pdx1-cre; LSL-KrasG12D;
P53R172H/+ and Ptf1a (P48)-cre; LSL-KrasG12D; Tgfbr2L/L mouse models8. A recent article
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highlighted the elusive link between chemoresistance and neutrophils, which suggested
that the expression of CD16 on the neutrophil surface was linked to a decreased efficacy
of chemotherapeutic drug capecitabine in colorectal cancer patients63. Low expression
of CD16 is commonly seen on immature neutrophils and potentially plays an
immunosuppressive role by suppressing natural killer (NK) cells and cytotoxic T- cells.
Neutrophils
Neutrophils are white blood cells of the granulocytic lineage. They are derived from
hematopoietic stem cells and mature in the bone marrow. About 1011 neutrophils are
generated every day, which makes up for their short life spans of less than 24 hours91.
Once fully matured, they circulate in the bloodstream and subsequently home in on
sources of inflammation in the tissue. They are highly efficient at extravasation and are
often dubbed as first responders to a pathogenic invasion. Neutrophils are largely proinflammatory in nature and can rapidly recruit other immune cells like dendritic cells and
T-cells to the site of infection through the release of cytokines like CCL3 9 and CXCL1210,
respectively. These cells are also very potent phagocytes and will usually assist in the
clearance of pathogenic invasions themselves. Neutrophils are intertwined with cancer
progression and are known to be involved in tumorigenesis, angiogenesis,
immunosuppression, and even metastasis in cancer2.

Neutrophil Structure
Neutrophils are relatively small cells with a diameter of around 15 micrometers.
Mature neutrophils consist of a well-defined multi-lobed (3-5) nucleus, inter-connected by
chromatin through histone proteins. As is typical of granulocytic cells, their cytoplasm
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contains a multitude of different granules, each able to release potent anti-microbial
enzymes upon activation.

Neutrophil Development and Life Span
Neutrophils originate from hematopoietic stem cells in the bone marrow. After
subsequent downstream signaling, these hematopoietic stem cells (HSC's) eventually
develop into granulocyte-monocyte progenitors (GMPs). Granulocyte colony-stimulating
factor (G-CSF), a type of growth factor/glycoprotein produced in the bone marrow, is
essential in the further differentiation of GMPs into myeloblasts, which eventually become
mature neutrophils11.
In order to preserve self-tolerance and homeostasis, the release of fully matured
neutrophils is highly regulated. Many chemotactic factors such as CXCL1, CXCL2,
complement factors like C3A and C5A, and even G-CSF can regulate the release of these
neutrophils through the bone marrow and into the bloodstream. These neutrophils follow
this chemokine trail into the inflammatory source, where they extravasate into the tissue.
Here, they recognize pattern recognition receptors (PRR's) on the pathogen, which
activate them to subsequently clear the pathogen by phagocytosis and the release of
other pro-inflammatory cytokines. In most cases, neutrophils, upon activation, shortly
undergo apoptosis and are cleared by the resident tissue macrophages. However, in the
context of cancer, we have observed that the neutrophil life span in the tumor is
abnormally prolonged, increasing the possibilities of crosstalk between neutrophils and
cancer.
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Neutrophil Methods of Activation
Depending on a multitude of different factors, the neutrophil can undergo three
different methods of activation:
1. Phagocytosis
Phagocytosis is the process by which cells engulf other cells or materials through
various receptor-mediated signaling processes. Neutrophils are often referred to as
'professional phagocytes' and readily internalize and subsequently destroy pathogens
through anti-microbial mechanisms. They have specialized receptors such as toll-like
receptors (TLRs), which recognize conserved molecular patterns known as pathogenassociated molecular patterns (PAMPs). They also recognize opsonized particles through
specific Fc receptors. Once the pathogen is recognized, it is subsequently internalized
into the neutrophil, with a specialized vacuole known as a phagosome forming around it.
This phagosome undergoes extensive remodeling events and eventually matures into a
vesicle with a more anti-microbial composition, killing the pathogen trapped inside 44.
In the context of cancer, neutrophils readily phagocytose opsonized tumor cells
through a process known as antibody-dependent cellular phagocytosis (ADCC)64.
However, tumor cells are usually larger than neutrophils, posing a challenge to the
complete phagocytosis carried out by neutrophils45.

2. Degranulation
Neutrophils can release anti-microbial enzymes from their granules into the TME
upon stimulation. As is expected from a cell of the granulocytic lineage, neutrophils host
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a vast arsenal of different granules, most of which are anti-microbial. They are four types
of granules expressed by the neutrophil. Azurophilic granules consist of bactericidal
enzymes like myeloperoxidase, hydrolases, cathepsin-G, and defensins92. Secondary
granules consist mainly of lactoferrin, an integral part of mucose and neutrophil
gelatinase-associated lipocalin92. Tertiary granules contain matrix metalloproteinase 9,
which is often linked with ECM remodeling92. Finally, secretory granules contain various
pathogen recognition receptors as well as complement receptors92. The degranulation
process is very tightly regulated through intracellular molecules B-arrestins and soluble
NSF attachment protein (SNAP)46.
Several enzymes released by neutrophils are linked to cancer progression. Matrix
metalloproteinase 9 (MMP9) primarily cleaves the ECM around the TME, which paves
the way for new blood vessel formation, called angiogenesis, which is a critical step
towards tumor progression. Arginase, also released by neutrophils, is widely known to
inhibit T-cell function and replication, preventing effective immune responses towards the
tumor.

3. NETosis
Neutrophil extracellular traps (NETs) result from a process termed as NETosis,
which culminates in the release of web-like structures composed of DNA fibers and
granular proteins and usually results in neutrophil death. NETs have had a controversial
history since their discovery in 200447. Initially thought to only bind to pathogens, impairing
their movement and eventually degrading them, the past 15 years have shed some light
on their involvement in various inflammatory diseases such as cancer48.
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The process of NETosis primarily involves the activation of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase, which provokes nuclear membrane
disintegration

and

chromatin

decondensation

through

neutrophil

elastase,

myeloperoxidase, and various histones, respectively49,50. Citrullinated histone 3 is
commonly used as a NET bio-marker. Neutrophil elastase and myeloperoxidase work
synergistically

together

by

degrading

various

histones,

causing

chromatin

decondensation49. This leads to the mixing of neutrophil granular proteins with chromatin,
and eventually, this amalgamation swells and ruptures the plasma membrane, resulting
in the violent expulsion of NETs. Neutrophils can partake in a milder, rapid form of
NETosis, known as vital NETosis, which remarkably retains some neutrophil functions
such as chemotaxis and phagocytosis and is independent of NADPH oxidase
formation51,52.
An abundance of various neutrophil activators in the TME, such as IL8 and
CXCR1/ CXCR2 ligands54,93, often creates a hospitable environment for NET formation.
Much like their precursor neutrophils, NETs have been implicated in both pro-tumor as
well as anti-tumorigenic capabilities48. They were shown to potentially orchestrate
circulating tumor cell extravasation by binding to them 53. This partnership also serves as
a mechanical barrier between tumor cells and other cytotoxic immune cells like natural
killer cells and cytotoxic T-cells, preventing physical contact between them and thereby
preventing tumor cell degradation54.
Neutrophil to lymphocyte ratio (NLR) in cancer
Inflammation, one of the seven hallmarks of cancer23, is a key factor in instigating
tumorigenesis in cancer. This systemic inflammation results in the invasion of many types
9

of immune cells into the tumor. Subsequently, these immune cells are activated and
release their cytokines, which causes even more inflammation in the tumor microenvironment, forming a positive feedback loop.
The NLR ratio is often described as an indicator for systemic inflammation and is
commonly used as a prognostic biomarker for tumor progression. The relative ease of
obtaining the NLR ratio from patients makes it an attractive biomarker. A high NLR ratio
often portrays large amounts of circulating neutrophils in the bloodstream, characteristic
of systemic inflammation, and can often result in elevated tumor-associated neutrophil
levels. Tumor-associated neutrophils (TANs) are often complicit in angiogenesis and
tumorigenesis through the release of MMP's and ROS radicals, respectively. They can
also

inhibit lymphocyte

maturation by releasing arginase, thus creating an

immunosuppressive environment. These reasons could potentially explain why there is
a relationship between high NLR ratios and the poor prognosis of patients.
Recent studies have shown that a higher NLR ratio leads to worse overall survival
in breast cancer patients12 and PDAC patients after surgical resection13. Xiang et al.
evaluated the efficacy of the NLR ratio in multiple PDAC patients who had undergone
surgical resection and suggested that this ratio can be used as a possible clinical
biomarker for PDAC. Similarly, Iwai et al. evaluated the NLR ratio in patients with
unresectable pancreatic cancer and derived similar conclusions65.
Neutrophil Recruitment in Cancer
As previously explained, HSC's possess the ability to differentiate into neutrophils.
Once these neutrophils are fully matured in the bone marrow, they are subsequently
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released into the bloodstream and are destined to circulate our bodies until they die.
However, through the complex interactions between selectins, integrins, and
chemokines, neutrophils are recruited to sites of inflammation in the tissue.
The smoldering inflammation around the tumor microenvironment is often primarily
responsible for recruiting neutrophils in the tumor area. A myriad of different chemokines
is involved in neutrophil recruitment observed in cancer. CXCL-8, commonly known as
the neutrophil recruitment factor, plays a well-established role in the chemotaxis of
neutrophils. Our lab has previously linked interleukin (IL)-8 secreted by breast tumors with
neutrophil recruitment. CXCL-8 binds to CXCR1, and CXCR2 receptors commonly
expressed on neutrophils, thus facilitating their movement into the tumor. IL-8 has also
been shown to induce angiogenesis, which is a critical step towards tumorigenesis14.
Himmel et al. showed that CXCL8 is also produced by regulatory T cells, which could be
another potential source for neutrophil recruitment15.
CXCL1 and CXCL2, highly expressed by tumor cells, are also potent chemokines
involved in neutrophil recruitment through the CXCL1-CXCR1 axis (Fig 1.1). Previous
studies have linked G-CSF with this axis and postulate that the combined effect stimulates
chemotaxis in neutrophils16. It is also interesting to note that tumor-associated neutrophils
also release CXCL1 and CXCL2 and can potentially attract circulating neutrophils into the
tumor themselves, thus creating a positive feedback loop.
Neutrophil Polarization
TANs are highly plastic and are known to polarize into different phenotypes
depending upon what signals they receive in the TME. They are polarized into either a
pro-inflammatory N1 phenotype or an anti-inflammatory N2 phenotype. This
11

nomenclature was derived from the M1/M2 classification used for macrophages. The
N1/N2 dichotomy is defined by their functional phenotypes, as no specific cell markers
have been discovered to date. This polarization depends on cytokine signals received in
the TME. Mishalian et al. suggest that the tumor stage (early or established) plays a role
in establishing the neutrophil phenotype55.
1. N1 Phenotype
Similar to neutrophils under normal homeostatic conditions, N1 neutrophil
subpopulations are short-lived, contain hyper-segmented nuclei, and are highly proinflammatory. This phenotype is primarily induced by the expression of interferon-beta
(IFN)-β in the TME56. They are pro-inflammatory in nature11 and are also known to display
direct tumor cell cytotoxicity by releasing potent anti-microbial substances like
peroxidases and nitric oxide or through ADCC25. Because of these reasons, N1
neutrophils are widely regarded as anti-tumorigenic in nature.
2. N2 Phenotype
In contrast, the N2 neutrophil phenotype is comparatively long-lived, has circular
nuclei, and is primarily immuno-suppressive. Transforming growth factor-beta (TGF-β) is
widely known to induce naïve TAN's into this phenotype. Coincidentally, TGF-β is highly
expressed in many tumor microenvironments, skewing TAN's distribution towards the N2
phenotype. The N2 neutrophil subpopulation is notoriously known to stimulate tumor
progression and growth. Its immunosuppressive abilities and increased arginase
expression prevent T-cell recruitment and maturation, allowing tumors to grow
unchecked66,67.

12

ROS and RNS radicals produced by these neutrophils have been shown to cause
genetic instability, promoting tumorigenesis in some cancer models68. They also release
MMP8 and MMP9, which cleave the ECM and activate VEGF, paving the way for new
blood vessels to form, which are crucial for developing tumors. These neutrophils are also
complicit in metastasis by releasing NE, which stimulates EMT in tumor cells.
The N1/ N2 classification model, although convenient, remains a controversial
classification. This is largely because of the absence of specific surface receptors and
difficulty to observe these neutrophil subtypes in human94. Moreover, secretory
substances released by these neutrophils, such as ROS, possess a dual role in cancer.
They can play an anti-tumorigenic role or a pro-tumorigenic role depending on their
concentrations95.

Neutrophil Survival in the TME
Neutrophils are universally considered to have a half-life of around 5.5 hours in the
bloodstream69. However, in the context of cancer, various reports advocate that they
persist in the TME for extended periods of time 70. It has been suggested that tumorderived cytokines may be responsible for the attenuation of neutrophil apoptosis 57,58,59.
TANs and tumors may work in tandem to increase each other's survival, as it was shown
that human and neck squamous adenocarcinomas increased neutrophil survival in vitro.
In contrast, these neutrophils expressed MMP-9, a well-established pro-angiogenic
factor60.
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Tumor-Associated Neutrophil Induced Immunosuppression
TAN's are widely known to have immunosuppressive abilities. These qualities
account for the tumor's unperturbed growth in the body. Ironically, neutrophils hinder other
cells in the innate immune system, such as antigen-presenting cells like macrophages
and dendritic cells. It was also reported that the crosstalk between myeloid-derived
suppressor cells (MDSCs) and macrophages was able to stimulate M2 polarization17.
TANs also debilitate NK cell function, which, together with the activity of cytotoxic T-cells,
constitute effective tumor cell destruction18. Despite sharing the same myeloid
precursors, MDSCs are always considered as pro-tumorigenic while neutrophils display
both pro-tumorigenic and anti-tumorigenic abilities96. MDSCs are also usually less dense
than neutrophils96. Youn et al. showed that tumor-bearing murine MDSC’s highly
expressed CD115 and CD244 relative to neutrophils and may be used as potential
surface receptors for the same97.
Although neutrophils have been shown to impair other innate immune cells, the
biggest blow of their immunosuppressive abilities is felt by T-cells, which play a critical
role in the adaptive immune system. Arginase-1, which is upregulated in N2 neutrophils,
has been shown to impair T-cell function. Degrading arginine also leads to cell cycle arrest
in T-cells, thus preventing replication.
Neutrophils are capable of recruiting regulatory T-cells known for their
immunosuppressive qualities and are also commonly associated with the downregulation
of other effector T-cells. Previous studies have shown that CD40, a receptor expressed
on MDSCs, interacts with regulatory T-cells and promotes their accumulation19. Another
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study showed that the activation of MDSCs through PGE2 reduced the proliferation of
CD4+CD25− T cells.
Activation of neutrophils through their specific surface Fc receptors often results in
ROS release through NADPH oxidase complex formation. ROS has been found to be
highly upregulated in MDSCs localized in murine tumors, often resulting in the
suppression of T-cell response20. It was also recently shown that co-culture assays of T
helper cells and neutrophils conditioned with tumor cell supernatant derived from gastric
cancer cells displayed a decrease in T cell proliferation21, which could likely be a result of
ROS expression by the neutrophils.
Neutrophils Complicit in Metastasis
Metastasis occurs when tumor cells originating from the primary tumor spread to
different organs of the body. Tumor cells detach from the primary tumor site, enter the
bloodstream, and subsequently extravasate into other organs 98. This advanced stage of
cancer is the leading cause of death in cancer-related deaths and is especially relevant
in the context of pancreatic cancer99.
Metastatic Cascade
The metastatic cascade is a marathon of complex and challenging events that a
tumor cell must overcome to progress towards the metastatic phase, including the
movement of the tumor cell from the primary site to the metastatic site, the second being
the colonization of the tumor cell at the metastatic site 22. Although metastasis is a highly
inefficient process, eventually, tumor cells will colonize distant organ sites. These cells
may develop into a secondary tumor, considered metastasis, resulting in a progressively
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worse prognosis. However, various immune cells are complicit in supporting these tumor
cells through the cascade. We will be talking about neutrophils in this regard.
Proliferation and Angiogenesis
Angiogenesis, or the formation of new blood vessels, is an essential process for
tumor cell proliferation. It feeds the tumor with a steady supply of oxygen and nutrients
from the blood. The angiogenic switch governs the extent of angiogenesis in our body
and typically maintains a healthy equilibrium between pro-angiogenic and anti-angiogenic
factors. However, in the context of tumor development, this switch remains in a perpetual
'on' state, skewing towards the formation of blood vessels. This is, in fact, so critical for
tumor development, it is often labeled as one of the hallmarks of cancer1,23.
There is a very significant relationship between angiogenesis and metastasis. Not
only does angiogenesis support tumor growth, accelerating its progression towards the
advanced metastatic stage, it also provides a critical pathway for detached tumor cells
from the primary site to enter the bloodstream. There have been many studies that have
linked metastasis with angiogenesis24.
TANs aid in the process of angiogenesis mainly in multiple ways. They are a major
source of vascular endothelial growth factor (VEGF), commonly known as a proangiogenic factor, which binds to resident epithelial cells, maintaining the 'on' state of the
angiogenic switch. They also release MMPs, which are notoriously known for remodeling
the ECM, giving the new blood vessels much-required space to grow25.
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EMT of Tumor Cells
Perhaps the defining feature of the metastatic cascade is the seemingly transient
change of tumor cell phenotype, from epithelial to mesenchymal. Initially, this pathway
was used by newly developed cells during embryonic development100. However, in the
context of metastasis, this transition is hijacked by tumor cells, allowing them to enter a
more mobile state, essentially giving them 'wings of freedom'.
This EMT transition is bought upon by various transcription factors such as Snail
and Twist101. Upon further downstream signaling, it results in a dwindling expression of
E-cadherin on the cell membrane26. Proteins responsible for strengthening the basement
membrane and tight junctions and gap junctions around the tumor cells are
downregulated because of these transcription factors, stimulating the transition from
epithelial to mesenchymal phenotype27. Correspondingly, this transition is characterized
by the up-regulation of proteins such as vimentin and N-cadherin28.
Many studies have linked TANs with the EMT transition observed in tumor cells. It
was recently shown that expression of specific mesenchymal markers was increased
when gastric cancer cells were treated with neutrophils in vitro29. They proposed that
neutrophils instigate the JAK2/STAT3 pathway in tumor cells through the release of IL17, resulting in EMT. In another study, a similar co-culture assay was performed using
neutrophils with human epithelial ovarian cancer cells, which resulted in a decrease of Ecadherin expression on the cancer cell30.
Circulating through the Bloodstream
Tumor cells that have successfully escaped from the confines of their primary
organ site and enter the bloodstream are called circulating tumor cells (CTCs). This long
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and arduous journey through the bloodstream is where most of these CTCs meet their
demise. A recent study even highlighted the possibility of using CTCs as a prognostic
biomarker in patients with metastatic breast cancer31. Current techniques for measuring
CTCs involve using epithelial cell adhesion molecule (EPCAM) as a surface marker,
which may underrepresent mesenchymal CTCs. In the context of PDAC, neutrophils were
found to be clustered around CTCs, potentially behaving as a physical protective barrier
against other cytotoxic immune cells like NK and cytotoxic T-cells32.
Extravasation
Extravasation is another crucial process involving the escape of the CTC into
distant tissue. CTCs may undergo a similar approach like leukocyte extravasation,
involving the complex process of selectin-mediated rolling, adhesions with the capillary
bed through integrin and cadherin expression 33. The homing of CTCs to a distant
metastatic site is not considered to be a random process. Most metastatic colonies in
PDAC are formed in the liver. This can be explained by Stephan Paget's legendary seed
and soil hypothesis, which suggests that interactions between the 'seed' (circulating tumor
cell) and the soil (existing microenvironment around the metastatic site) are responsible
for determining the secondary metastatic site102.
Relatively recent literature suggests that neutrophils help in CTC extravasation by
protecting them from natural killer (NK) cells, which are very effective tumor cell killers34.
Through intravital microscopy, another group of scientists showed that neutrophils might
assist in circulating tumor cell adhesion in their murine model for liver metastasis 35.
Neutrophils may also possibly behave as a 'chaperone' to CTCs through the interaction
between tumor cell-expressed ICAM-1 and various neutrophil receptors36,37.
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Establishment of metastasis in the secondary site
The final obstacle faced by tumor cells in the metastatic cascade is to establish the
secondary metastatic site. According to Paget's seed and soil hypothesis, the soil (the
tumor micro-environment) is a major factor in determining the destiny of an invading tumor
cell at the secondary site. The establishment of this 'pre-metastatic niche' is considered
to take precedence even before CTC invasion38. Paget et al. showed that bone marrowderived hematopoietic cells were linked with metastasis through the expression of
VEGFR1.

Similar

to

the

primary

tumor

site,

a

largely

immunosuppressive

microenvironment persists in pre-metastatic niches. MDSC's, which suppress T-cell
activity, are commonly found in these niches39. Surprisingly enough, TIMP1, primarily
released by tumor cells, was also involved in niche formation in the liver through
neutrophils40. G-CSF, a potent growth factor of neutrophils, was also seen to be
upregulated in certain tumors and subsequently involved in premetastatic niche formation
in the lung, again through the recruitment of neutrophils41. Although EMT is a crucial step
in metastasis, it is also theorized that MET, mesenchymal-to-epithelial transition, also
occurs during this colonization phase42. The TME hosts a range of infiltrating immune
cells and resident stromal cells interacting with these tumor cells. Previous literature
suggests that myeloid cells stimulate tumor cell proliferation by releasing versican, a large
proteoglycan43.

Conclusion
Although science has made significant improvements in fighting pancreatic cancer,
a long road lies ahead of us. Due to their short lifespans, neutrophils have usually been
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ignored in cancer progression in the past. However, the last decade of research
elucidates a fresh new role of neutrophils in cancer. Tumor cells stimulate the polarization
of naïve TANs into the pro-tumorigenic state. Immunosuppressive abilities characterize
this state, thwarting other cytotoxic immune cells in destroying the tumor cells and
promoting angiogenesis, crucial for tumorigenesis and eventually metastasis. TANs also
have a longer lifespan and are able to persist in the TME for long periods. They may also
undergo NETosis, and become NET's, which are linked with cancer progression.
Neutrophils have also been implicated in being complicit in metastasis and assisting
tumor cells in each step of the metastatic cascade.
Due to their critical involvement in tumor progression, neutrophils turn into
attractive targets for novel immunotherapeutic strategies. Fridlender et al. have shown
that blocking TGF-β in the TME resulted in an increase in neutrophils of the antitumorigenic phenotype67. Jablonska et al. showed that inactivating the IFN-β gene in their
murine melanoma model led to increased tumor proliferation and angiogenesis, caused
by the increased infiltration of pro-tumorigenic neutrophils75. Thus, by steering the
polarization of naïve TANs in the TME, we can potentially improve cancer therapeutics.
The working hypothesis of my thesis is that pancreatic ductal adenocarcinoma
(PDAC) cells prime the neutrophils to become pro-tumorigenic. Three specific objectives
are Objective 1: Is PDAC progression associated with neutrophil infiltration? Objective
2: Why do we see an increase in neutrophil infiltration in the tumor microenvironment?
Objective 3: What roles are neutrophil extracellular traps playing in the tumor
microenvironment? To achieve these objectives, we performed immunofluorescence
experiments on PDAC tissue from murine mouse models, using MPO, cathepsin-G, and
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citrullinated histone 3 as markers. We also performed co-culture assays and measured
survival using the WST assay. Finally, we examined the expression of multiple secretory
factors in undifferentiated and differentiated neutrophils treated with tumor cell
supernatant. We hope that our work here can further the understanding of neutrophil
involvement in pancreatic cancer progression.
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Figure 1.1: Neutrophil recruitment into the TME
Neutrophils in the bloodstream extravasate into the TME by following the
chemokine gradient set by the tumor cells.

23

MATERIALS AND METHODS
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Cell Lines
We selected multiple human pancreatic adenocarcinoma cell lines derived from
either the primary tumor or metastatic sites. This criterion was utilized to investigate
whether the metastatic potential of a particular tumor cell line had any significant effect
on our results.
Human PDAC cell lines L3.3, L3.6pl, AsPC3, T3M4, and CD18/HPAF, were
cultured in the recommended media consisting of Dulbecco's Modified Eagle's Medium
(Sigma-Aldrich, St. Louis, MO, U.S.A.) supplemented with 5% fetal bovine serum (F.B.S.)
(Sigma-Aldrich), 2-mM L-glutamine (Mediatech, Herdon, VA, U.S.A.), 1% vitamins
(Mediatech), and 0.08% gentamycin (Invitrogen, Carlsbad, CA, U.S.A.)89.
Additionally, the BXPC3 cell line, which was derived from the primary
adenocarcinoma of a human patient, was cultured in Roswell Park Memorial Institute
media 1640 (Sigma-Aldrich, St. Louis, MO, U.S.A.) supplemented with 5% F.B.S. (SigmaAldrich), 2-mM L-glutamine (Mediatech, Herdon, VA, U.S.A.), 1% vitamins (Mediatech),
and 0.08% gentamycin (Invitrogen, Carlsbad, CA, U.S.A.).
Tumor cell supernatant was collected by plating 6 million cells in a 100 mm petri
dish in serum-containing media. This media was subsequently replaced by serum-free
media the next day, and the supernatant was collected 24-72 hours after.
The human leukemia cell line HL60, which displays promyelocytic characteristics,
was derived from a patient suffering from acute promyelocytic leukemia and was cultured
in identical media as the BXPC3 cell line. This cell line was subsequently differentiated
using the protocol described by Gupta et.al90, where they used 1.25% DMSO and 1 μM
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ATRA dissolved in trans-retinoic acid for five days. Morphology of the differentiated cells
was observed by cytospinning 5 × 104 cells in the Cytopro on glass slides, which were
subsequently visualized through the Wright-Giemsa stain.
The murine MPRO Cell Line, Clone 2.1 (MPRO) (murine promyelocytes from
ATCC, Manassas, VA, U.S.A.) was cultured in Iscove's Modified Dulbecco's Medium
(IMDM, Sigma Aldrich, St. Louis, MO, U.S.A.) with 4 mM L-glutamine, 10 ng/mL murine
granulocyte-macrophage colony-stimulating factor (GM-CSF, Peprotech, Pittsburgh, PA,
U.S.A.), and 20% heat-inactivated horse serum (Sigma Aldrich)58.
Live murine neutrophils were received as a generous gift from Dr. Leah Cook's lab,
University of Nebraska Medical Center.
Cell Viability Assay
MPRO, HL60 differentiated, and HL60 undifferentiated cells (3 × 105 per well in a
96-well plate) were treated with supernatants derived from T3M4, CD18/HPAF, ASPC3,
BXPC3 cell lines, and serum-free media for 24 hours in various dilutions of supernatant
(87.5%, 75%, 50%, 25%) using serum-free media as a control. After overnight treatment,
W.S.T. (Sigma Aldrich, Milwaukee, WI, U.S.A.) was added to each well as recommended
by the manufacturer for four hours, and the plate was subsequently measured for
absorbance at a wavelength of 450 nm using an ELx800 (Bio-Tek, Winooski, VT, U.S.A.)
plate reader. Percent growth was calculated as ([Absorbance of the treatment Absorbance of the control group]/ average of the control group).
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Co-Culture Assay
T3M4 and CD18/HPAF cell lines were added to a 96-well plate (5000 per well) and
incubated overnight in serum-containing media. The next day, the media was changed,
and MPRO, HL60 differentiated, and HL60 undifferentiated cells were added to the tumor
cells' wells. After 24-hour incubation, the neutrophils were collected and transferred to
new wells while the media of the tumor cells was replaced again with serum-containing
media. W.S.T. (Sigma Aldrich, Milwaukee, WI, U.S.A.) was added to each well as
described above, and the plate was measured for the absorbance at a wavelength of 450
nm using an ELx800 (Bio-Tek, Winooski, VT, U.S.A.) plate reader. Percent growth was
calculated as ([Absorbance of the treatment- Absorbance of the control group]/ average
of the control group).
Immunofluorescence
Murine pancreatic cancer tissue slides from animal models (KC: K-rasLSL.G12D/+;
Pdx-1-Cre) and (KCC: K-rasLSL.G12D/+; Pdx-1-Cre; Cxcr2+/-) were obtained through Dr.
Surinder Batra's lab at the University of Nebraska, Medical Center. These tissue sections
were deparaffinized in xylene followed by rehydration in 70% ethyl alcohol. The tissue
region was marked with a P.A.P. pen and was subsequently washed three times with
phosphate-buffered saline (PBS). The slides were blocked using blocking buffer (10%
goat serum) for one hour and then stained with primary antibodies (Table 2.1) overnight
at 4C.

The slides were washed with PBS the next day, and a secondary

immunofluorescence antibody (Table 2.1) was added. After a one-hour incubation at
room temperature, the slides were rewashed with PBS, VectaFluor™ Duet
Immunofluorescence Double Labeling Kit (Vector Laboratories, Burlingame, CA, was
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added, and a coverslip was added on the tissue section. The slides were observed under
a Nikon Eclipse E800 microscope (Nikon, Melville, NY, U.S.A.) and NIS-Elements BR
5.11.00 software (Nikon). The numbers of neutrophils and NETs were calculated per high
power frame. The list of antibodies used can be found in Table 2.1.
Gene Expression Analysis
RNA Isolation
Total RNA from neutrophil cell lines was isolated by spinning the cells down,
washing them with PBS, subsequently followed by lysing the pellet in 1 ml TRIzol reagent
(Invitrogen, Carlsbad, CA). Then, 0.2 ml chloroform was added to the sample. These
samples were then centrifuged at 12000g for 15 minutes at 4C and the clear aqueous
phase was transferred to separate tubes. An equal volume of isopropanol was added to
each tube to precipitate the RNA and was incubated at room temperature for 10 minutes.
Subsequently, these tubes were centrifuged at 12000g for 10 minutes at 4C. The
supernatant was discarded, and the pellet was washed in 1 ml of 75% ethanol. The
sample was centrifuged once more at 7500g for 5 minutes at 4C. The supernatant was
discarded, and the remaining pellet was dissolved in 20 l diethyl pyrocarbonate water.
We measured the concentration of RNA using a Thermo Scientific NanoDrop 2000
Spectrophotometer (Thermo Scientific, Carlsbad, CA).
Quantitative RT-PCR
Five µg of total RNA was used to prepare complementary DNA using
SuperScriptTM Reverse Transcriptase (Invitrogen) and oligo (dT) primers. The
complementary DNA (cDNA) was stored at -20C until further use.
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We quantified human CXCL1, CXCL2, CXCL8, IL23, INOS, TGFB, TNFA, MMP9, along
with RPL13A (to normalize gene expression). These experiments were performed using
PowerUp SYBR Green Master Mix (Applied Biosystems, Thermo Fisher Scientific) and
primers (Table 2.2). The cDNA was diluted to a 1:5 ratio. The Quant Studio 3 Real-Time
PCR Detection System (Thermo Fisher Scientific) and the Quant Studio design and
analysis software were used to run and analyze the experiments. (-∆Ct) was calculated
by the difference between cycle time (C.T.) housekeeping gene RPL13A and target
specific C.T. Relative expression was calculated as (2(-∆Ct)). Subsequently, we calculated
fold change (2(-∆∆Ct)) by comparing mRNA expression of target gene(2(-∆Ct)) vs. RPL13A(2(∆Ct))

and normalizing it to serum-free HL60 (2(-∆∆Ct)) and differentiated HL60 (2(-∆∆Ct))

expression. The list of gene-specific primers used can be found in Table 2.2.
Neutrophil Extracellular Trap Quantification Assay
5 x 104 undifferentiated HL60 cells were plated in a 96-well plate and treated with
supernatants derived from CD18/HPAF supernatants and serum-free media for 2 hours.
Phorbol 12-myristate 13-acetate (Sigma) was added to the positive control for 2 hours at
20 nM prior to reading the plate. 10 nM of Sytox Green (Invitrogen) was added to each
sample 15 minutes prior to measuring the plate via an EVOS FL auto microscope. The
number of green fluorescent NETs was counted per HPF. Representative pictures were
also taken through this microscope.
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Table 2.1
Antibody
Source
Murine Anti-Histone H3 (citrulline R2 + R8 Abcam, MA, U.S.A, ab5103
+ R17) antibody
Murine Anti-Myeloperoxidase
Abcam, MA, U.S.A.
Murine Anti-Cathepsin G
Biotinylated
Antibody

Goat

Anti-Rabbit

Dilution
1:200
IF
1:100
IF
Santa
Cruz,
SC
6514 1:100
Biotechnology, Europe
IF
IgG Vector Laboratories, CA, 1:500
U.S.A.
IF
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Table 2.2 List of Primers
TNF-A
GRO1
GRO2
GRO3
TGFB2
MMP9
CXCL8
Il23
IL17
INOS
RPL13A

Forward 5’-GAGCTGAGAGATAACCAGCTGGTG-3'
Reverse 3- GAGATAGATGGGCTCATACCAGGG
Forward 5’-ATTCACCCCAAGAACATCCC-3'
Reverse 5’-CACCAGTGAGCTTCCTCCT-3'
Forward 5’-GCAGGGAATTCACCTCAAG-3’
Reverse 5’-AGCTTCCTCCTTCCTTCTG-3'
Forward 5’-GCAGGGAATTCACCTCAAG-3’
Reverse 5’-GGTGCTCCCCTTGTTCAGT-3'
Forward 5’-CAGCACACTCGATATGGACCA-3'
Reverse 5’-CCTCGGGGCTCAGGATAGTCT-3'
Forward 5’-CATCGTCATCCAGTTTGGTG-3'
Reverse 5’-AGGGACCACAACTCGTCATC-3'
Forward 5’-ACATACTCCAAACCTTTTCCACCC-3'
Reverse 5’-CAACCCTCTGCACCCAGTTTTC-3'
Forward 5’-TGCAAAGGATCCACCAGGGTCTGA-3'
Reverse 5’-TAGGTGCCATCCTTGAGCTGCTGC-3'
Forward 5’-AGATTACTACAACCGATCCACCT-3'
Reverse 5’-GGGGACAGAGTTCATGTGGTA-3'
Forward 5’-TCCAAGACACACTTCACC-3'
Reverse 5’-TTCCTGTTGTTTCTATCTCC-3'
Forward 5’-CCTGGAGGAGAACAGGAAAGAGA-3'
Reverse 5-TTGAGGACCTCTGTGTATTTGTCAA-3'
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RESULTS
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Neutrophil Infiltration increased as PDAC progressed and is dependent on the
CXCR2 receptor
A systemic increase of neutrophils in circulation is often observed in PDAC, evident
through the high NLR ratios measured in patients with non-resectable PDAC65. Large
numbers of CXCR2+ neutrophils are also recruited in the TME and are often facilitated by
various chemokines such as CXCL1, CXCL2, and CXCL8 released by the tumor.
We investigated whether our pancreatic mouse model increased neutrophil
infiltration in tumors from KC animal models (KC: K-rasLSL.G12D/+; Pdx-1-Cre) at different
time points by immunostaining the tissue sections for MPO and cathepsin-G (FIG 2.1).
We observed an increase in neutrophil infiltration as the tumor progressed from 10 weeks
to 50 weeks.
Based on previous studies in our lab76, we hypothesized that the CXCR2 receptor
on the neutrophils was responsible for the increased recruitment. We performed similar
MPO and cathepsin-G immunostaining on tumors from CXCR2 knocked out KC mice
(KCC: K-rasLSL;G12D/+; Pdx-1-Cre; Cxcr2+/-) and observed a significant decrease in
neutrophil infiltration when compared with our wild type KC murine model (FIG 2.2).
These results suggest that neutrophil recruitment in the TME becomes more intense as
PDAC progresses and is linked with the host CXCR2 receptor.
The PC cell-free supernatant enhanced neutrophil survival
Although neutrophils are universally considered short-lived cells, there has been
mounting evidence suggesting that neutrophils in the TME survive for extended periods
of time77. To investigate whether neutrophils exhibit a similar effect in the PDAC TME, we
treated undifferentiated and differentiated human HL60 and murine MPRO cells for 24
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hours with supernatants derived from CD18, gemcitabine resistant CD18 (CD18GR),
T3M4, gemcitabine resistant T3M4 (T3M4GR), BXPC-3 and AXPC1 tumor cell lines (FIG
2.3).

We found that the HL60 cells exhibited higher survival in a concentrations

dependent-manner (v/v) when treated with tumor cell supernatants than control-treated
with serum-free (SF) media. The differentiated HL60 cells also produced a similar result.
Murine neutrophils also displayed higher survival when treated with CD18 and CD18GR
cell supernatants. Meanwhile, we also attempted to treat MPRO cells with tumor cell
supernatant for 72 hours; however, we observed a significant change in neutrophil
survival at the higher concentrations (75% v/v). These results suggest that
undifferentiated and differentiated neutrophils can survive in the PDAC TME for more
extended periods.
Co-culture assay between tumor cells and neutrophils increased tumor cell
survival and decreased neutrophil survival
After examining the effect of tumor cell supernatant on the survival of neutrophils,
we proceeded to investigate how the direct interaction between tumor cells and
neutrophils affected their survivability. We co-cultured MPRO cells and undifferentiated
and differentiated HL60 cells with CD18, CD18GR, T3M4, and T3M4GR tumor cells for
24 hours. We then separated the neutrophils and tumor cells and measured their survival
compared to controls treated with SF media. We observed a significant increase in the
survival of most tumor cell lines when treated with neutrophils (FIG 2.4). Surprisingly
enough, we did not observe an increase in CD18 tumor cell survival when co-cultured
with undifferentiated HL60 neutrophils.
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Moreover, our co-culture assay displayed a significant decrease in MPRO and
differentiated HL60 neutrophil survival (FIG 2.5). Undifferentiated HL60 survival remained
unchanged during this experiment. These results indicate that the interaction between
neutrophils and tumor cells in the TME of PDAC can reasonably increase the survival of
tumor cells in PDAC and correspondingly result in a decrease in neutrophil survival.
Neutrophils cultured in the PC supernatant secreted anti-tumor factors
We treated undifferentiated and differentiated HL60 neutrophils with supernatant
derived from ASPC1 and BXPC3 tumor cell lines to further investigate the neutrophiltumor cell interaction. We measured the expression of various secretory factors (Fig 2.6,
2.7, 2.8, 2.9). Our undifferentiated HL60 cells displayed a decrease in CXCL1 and TGFbeta expression (Fig 2.6). CXCL2, iNOS, CXCL8, IL23, and TNFA expression remain
unchanged. We also observed no significant difference in the expression of any secretory
factors in our differentiated HL60 neutrophils (Fig 2.7). Also, our differentiated HL60 cells
displayed a significant increase in CXCL2, CXCL8, and IL23 expression and a significant
decrease in CXCL1 and iNOS expression compared to undifferentiated HL60 cells in
serum-free media (Fig 2.8). Finally, the differentiated neutrophils significantly increased
CXCL1, CXCL8, and IL23 expression (Fig 2.9).
NET Infiltration increased as PDAC progressed and is dependent on the CXCR2
receptor
NETs discovered in 2004 by Brinkmann et al.
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have been widely implicated in

cancer progression. They are known to orchestrate circulating tumor cell (CTC)
extravasation, impair the immune system, and release proteases such as MMP948,53.
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We found that our KC pancreatic mouse model also showed an increase in NETs as the
disease progressed in its later stages (Fig 2.10). Like our previous studies examining
neutrophil infiltration, we also looked at the NET expression in our KC and KCC model
and observed a significant decrease in NET counts (Fig 2.11).
We also discovered that NET formation was favored when neutrophils were treated
with tumor cell supernatants derived from L3.3 and L3.6 cell lines (Fig 2.12). These
results suggest that neutrophil infiltration and NET formation are closely tied to each
other, and the TME in PDAC might stimulate NETosis in these neutrophils.
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Figure 2.1: Neutrophil Infiltration increased as PDAC progressed in our KC model
(A) Quantitative measurement of MPO positive neutrophils in our KC progressive murine
model. (B) Representative immunofluorescence imaging of MPO positive neutrophils in
our KC progressive murine model. (C) Quantitative measurement of cathepsin-G positive
neutrophils in our KC progressive murine model. (D) Representative immunofluorescence
imaging of cathepsin G positive neutrophils in our KC progressive murine model. The
values are shown as mean ± SEM, Unpaired t-test; * for P<0.05; ** for P< 0.01. The
pictures were acquired under a magnification of 200X. The scale bars are shown as 10
m.
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Figure 2.2: Neutrophil Infiltration decreased in our murine KCC model
(A) Quantitative measurement of MPO positive neutrophils in our KC and KCC murine
model. (B) Representative immunofluorescence imaging of MPO positive neutrophils in
our KC and KCC murine model. The values are shown as mean ± SEM, Unpaired t-test,**
for P< 0.01. The pictures were acquired under a magnification of 200X. The scale bars
are shown as 10 m.
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Figure 2.3: The supernatant of CD18, CD18GR, ASPC, T3M4, and BXPC3 enhanced
the survivability of undifferentiated MPRO cells, differentiated and undifferentiated
HL60 cells
(A) The supernatant of CD18 and CD18GR cells significantly enhanced the survival of
undifferentiated HL60 cells. (B) The supernatant of CD18 and CD18GR cells significantly
enhanced the survival of undifferentiated MPRO cells. (C) The supernatant of CD18,
CD18GR ASPC, BXPC3, and T3M4 cells significantly enhanced the survival of
differentiated HL60 cells. (D) The supernatant of CD18 cells had no significant ability to
increase the survival of MPRO neutrophils treated for 72 hours. (E) The supernatant of
CD18 and CD18GR cells significantly enhanced the survival of murine neutrophils. The
values are shown as mean ± SEM, Unpaired t-test; * for P<0.05; ** for P< 0.01; *** for P
≤ 0.001; **** for P ≤ 0.000
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Figure 2.4: The co-culture assay using CD18, CD18GR, T3M4, T3M4GR cells, and
undifferentiated MPRO cells, differentiated and undifferentiated HL60 cells
enhanced tumor cell survival
(A) The co-culture assay, including CD18, CD18GR cells, and undifferentiated MPRO
cells, enhanced tumor cell survival. (B) The co-culture assay involving T3M4, T3M4GR
cells, and undifferentiated MPRO cells enhanced tumor cell survival. (C) The co-culture
assay utilizing CD18 cells and undifferentiated and differentiated HL60 cells did not affect
tumor cell survival. (D) The co-culture assay that included T3M4 cells and undifferentiated
and differentiated HL60 cells enhanced tumor cell survival. The values are shown as
mean ± SEM, Unpaired t-test; * for P<0.05; ** for P< 0.01; *** for P ≤ 0.001; **** for P ≤
0.0001.
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Figure 2.5: The co-culture assay including CD18, CD18GR, T3M4, T3M4GR cells,
and undifferentiated MPRO cells, differentiated and undifferentiated HL60 cells
decreased neutrophil cell survival
(A) The co-culture assay involving CD18, CD18GR cells, and undifferentiated MPRO
cells decreased neutrophil survival. (B) The co-culture assay using T3M4, T3M4GR cells,
and undifferentiated MPRO cells decreased neutrophil survival. (C) The co-culture assay
between CD18 cells and undifferentiated and differentiated HL60 cells did not affect
neutrophil cell survival. (D) The co-culture assay of T3M4 cells and undifferentiated as
well as differentiated HL60 cells decreased neutrophil survival. The values are shown as
mean ± SEM, Unpaired t-test; * for P<0.05; ** for P< 0.01; *** for P ≤ 0.001; **** for P ≤
0.0001.
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Figure 2.6: Undifferentiated HL60 cells cultured in tumor cell supernatant
downregulated pro-tumor factors CXCL1 and TGFB
(A) Quantitative RT-PCR for the expression of CXCL1 in undifferentiated HL60 cells
cultured in serum-free media and supernatant derived from ASPC tumor cells. (B)
Quantitative RT-PCR for the expression of TGFB in undifferentiated HL60 cells cultured
in serum-free media and supernatant derived from ASPC tumor cells. (C) Quantitative
RT-PCR for the expression of CXCL2 in undifferentiated HL60 cells cultured in SF media
and supernatant derived from ASPC tumor cells. (D) Quantitative RT-PCR for the
expression of iNOS in undifferentiated HL60 cells cultured in serum-free media and
supernatant derived from ASPC tumor cells. (E) Quantitative RT-PCR for the expression
of IL23 in undifferentiated HL60 cells cultured in serum-free media and supernatant
derived from ASPC tumor cells. (F) Quantitative RT-PCR for the expression of CXCL8 in
undifferentiated HL60 cells cultured in serum-free media and supernatant derived from
ASPC tumor cells. (G) Quantitative RT-PCR for the expression of TNFA in
undifferentiated HL60 cells cultured in serum-free media and supernatant derived from
ASPC tumor cells. The values are mean fold change ± SEM; unpaired t-test, assume both
populations have the same SD; **P <0.005; *P<0.0001; *** for P ≤ 0.05.
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Figure 2.7: Differentiated HL60 cells cultured in tumor cell supernatant displayed
no significant changes in secretory factors
(A) Quantitative RT-PCR for the expression of CXCL1 in differentiated HL60 cells cultured
in serum-free media and supernatant derived from ASPC tumor cells. (B) Quantitative
RT-PCR for the expression of CXCL2 in differentiated HL60 cells cultured in serum-free
media and supernatant derived from ASPC tumor cells. (C) Quantitative RT-PCR for the
expression of IL23 in differentiated HL60 cells cultured in serum-free media and
supernatant derived from ASPC tumor cells. (D) Quantitative RT-PCR for the expression
of CXCL8 in differentiated HL60 cells cultured in serum-free media and supernatant
derived from ASPC tumor cells. (E) Quantitative RT-PCR for the expression of TGFB in
differentiated HL60 cells cultured in serum-free media and supernatant derived from
ASPC tumor cells. (F) Quantitative RT-PCR for the expression of iNOS in differentiated
HL60 cells cultured in serum-free media and supernatant derived from ASPC tumor cells.
(G) Quantitative RT-PCR for the expression of TNFA in differentiated HL60 cells cultured
in serum-free media and supernatant derived from ASPC tumor cells. The values are
mean fold change ± SEM; unpaired t-test, assuming both populations have the same SD;
**P <0.005; *P<0.0001; *** for P ≤ 0.05.
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Figure 2.8: Differentiated and undifferentiated HL60 cells cultured in SF media
displayed significant changes in secretory factors IL23, CXCL2, CXCL8, CXCL1,
and iNOS
(A) Quantitative RT-PCR for the expression of IL23 in differentiated and undifferentiated
HL60 cells cultured in SF media. (B) Quantitative RT-PCR for the expression of CXCL2
in differentiated and undifferentiated HL60 cells cultured in SF media. (C) Quantitative
RT-PCR for the expression of CXCL8 in differentiated and undifferentiated HL60 cells
cultured in SF media. (D) Quantitative RT-PCR for the expression of CXCL1 in
differentiated and undifferentiated HL60 cells cultured in SF media. (E) Quantitative RTPCR for the expression of iNOS in differentiated and undifferentiated HL60 cells cultured
in SF media. (F) Quantitative RT-PCR for the expression of TNFA in differentiated and
undifferentiated HL60 cells cultured in SF media. (G) Quantitative RT-PCR for the
expression of TGFB in differentiated and undifferentiated HL60 cells cultured in SF media.
The values are mean relative expression ± SEM; unpaired t-test, assume both
populations have the same SD; **P <0.005; *P<0.0001; *** for P ≤ 0.05.
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Figure 2.9: Differentiated and undifferentiated HL60 cells cultured in ASPC derived
supernatant displayed a significant increase in secretory factors IL23, CXCL8,
CXCL1 expression
(A) Quantitative RT-PCR for the expression of IL23 in differentiated and undifferentiated
HL60 cells cultured in ASPC derived supernatant. (B) Quantitative RT-PCR for the
expression of CXCL8 in differentiated and undifferentiated HL60 cells cultured in ASPC
derived supernatant. (C) Quantitative RT-PCR for the expression of CXCL1 in
differentiated and undifferentiated HL60 cells cultured in ASPC derived supernatant. (D)
Quantitative RT-PCR for the expression of CXCL2 in differentiated and undifferentiated
HL60 cells cultured ASPC derived supernatant. (E) Quantitative RT-PCR for the
expression of TNFA in differentiated and undifferentiated HL60 cells cultured in ASPC
derived supernatant. (F) Quantitative RT-PCR for the expression of TGFB in differentiated
and undifferentiated HL60 cells cultured in ASPC derived supernatant. (G) Quantitative
RT-PCR for the expression of iNOS in differentiated and undifferentiated HL60 cells
cultured in ASPC-derived supernatant. The values are mean relative expression ± SEM;
unpaired t-test, assume both populations have the same SD; **P <0.005; *P<0.0001; ***
for P ≤ 0.05.
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Figure 2.10: NET Infiltration increased as PDAC progressed in our KC model
(A) Quantitative measurement of citrullinated histone 3 positive NET's in our KC
progressive murine model. (B) Representative immunofluorescence imaging of
citrullinated histone 3 positive NET in our KC progressive murine model. The values are
shown as mean ± SEM, Unpaired t-test; * for P<0.05.
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Figure 2.11: NET Infiltration decreased in our murine KCC model
(A) Quantitative measurement of citrullinated histone positive NET's in our KC and KCC
murine model. (B) Representative immunofluorescence imaging of citrullinated histone
3 positive NET's in our KC and KCC murine model. The values are shown as mean ±
SEM, Unpaired t-test,** for P< 0.01. The pictures were acquired under a magnification of
200X. The scale bars are shown as 10 m.
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Figure 2.12: NET counts increased when treated with supernatant derived from L3.3
and L3.6 tumor cell-derived supernatant
(A) Representative immunofluorescence imaging of Sytox green positive NETs treated
with SF media (negative control), SF media with 20 nM PMA (positive control), and tumor
cell supernatant derived from L3.3 and L3.6 tumor cell lines. (B) Quantitative
measurement of Sytox green positive NETs treated with SF media (negative control) and
tumor cell supernatant derived from L3.3 and L3.6 tumor cell lines.
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DISCUSSION
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One of the established hallmarks of cancer is persistent, chronic inflammation in
the TME. This inflammation is induced by two pathways78. The intrinsic pathway involves
genetic mutations, resulting in oncogene activation and diminished tumor suppressor
activation. This is commonly observed in PDAC, where the KRAS mutation is often the
initiating event of tumorigenesis and is present in 90% of all PDAC tumors 76. This gene
encodes the KRAS protein, commonly associated with cell proliferation and
differentiation, and is highly upregulated in PDAC76. The other pathway of inflammation
involves inflammation generated by the TME78. The TME in PDAC is complex and
dynamic, consisting of stromal cells, fibroblasts, immune cells, and desmoplasia103.
Invading leukocytes such as macrophages and neutrophils are highly prone to release
ROS and RNS upon activation, often orchestrating downstream inflammatory pathways
in the tumor.
Neutrophils, the most abundant white blood cells in our body, play a dubious role
in tumor progression. On the one hand, many reports have observed neutrophils carrying
out their normal anti-tumor responses, involving inflammation and cytotoxicity104.
However, an increasing number of studies show that neutrophils play a pro-tumorigenic
role in cancer progression by fostering an immunosuppressive environment, driving
angiogenesis, and releasing proteinases104. This theory is further cemented in PDAC,
where a high NLR ratio indicates poor prognosis in patients13. This seemingly conflicting
nature of these immune cells can, in theory, be interpreted by the presence of different
subpopulations of neutrophils in the body67. However, this classification is highly
controversial, and much work needs to be done in this area. In this study, we investigated
the neutrophil-tumor interaction in PDAC.
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Our first set of experiments investigated neutrophil invasion in the TME of PDAC.
Our KC mouse model Pdx1-cre;LSL-Kras(G12D) displayed increased neutrophil numbers
as the disease progressed towards its late stages (Fig 2.1). These results are coincident
with other studies indicating that elevated neutrophil infiltration leads to poor prognosis in
PDAC79. The PDAC TME establishes high expression of the chemotactic cytokines
CXCL1, CXCL2, and CXCL5, and neutrophils are attracted to these regions due to their
expression of surface receptor CXCR2. The CXCR2 receptor specifically binds to the
cytokines mentioned above and is thus involved in chemotaxis. Neutrophils also can
release these chemotactic cytokines themselves once activated and possess the ability
to create a positive feedback loop in the TME. We observed impaired neutrophil invasion
in our CXCR2+/- Cre-LSL-KrasG12D murine model (Fig 2.2). This opens the possibilities of
therapeutic strategies involving blocking the CXCR2 receptors, thus decreasing
neutrophil invasion leading to potentially improved prognosis.
Once we established an increase in neutrophil numbers as PDAC progressed, we
investigated the capability of tumor cells to favor neutrophil survival. Neutrophils were
previously ignored in cancer research due to their short lifespan. However, recent reports
suggest enhanced neutrophil survival in the TME58. Our experiments determined a
significant increase in neutrophil survival when treated with supernatants derived from
multiple PDAC cell lines (Fig 2.3). These results suggest that neutrophils survive for more
extended periods in the PDAC TME. Previous findings suggest that tumors upregulate
the expression of the critical neutrophil growth factors G-CSF and GM-CSF, thus creating
an environment favoring neutrophil survival in the TME57.
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Moreover, Zhang et al. have recently shown that high expression of G-CSF in
human PDAC patients led to an overall poor prognosis80. This could be the result of an
influx of immunosuppressive neutrophils in the TME. Thus, our studies reaffirm that the
TME fosters neutrophil survival in PDAC.
Neutrophils are well established in promoting tumor proliferation in many cancer
types. N2 neutrophils behave as anti-inflammatory neutrophils and are involved in
immunosuppression and angiogenesis, critical milestones responsible for tumor
development and even metastasis. Our co-culture assay (Fig 2.4) determined that
neutrophil-tumor cell interaction in proximity increased tumor cell survival. Recently,
Lianyuan et al. showed similar results where their PDAC cell lines displayed increased
survival when co-cultured with neutrophils at low density81.
However, our co-culture assay also led to a decrease in neutrophil survival (Fig
2.5). This was a very surprising outcome, which leads us to hypothesize that these
neutrophils undergo NETosis, resulting in neutrophil cell death and the formation of
NET's. NET's have been mainly implicated in facilitating metastasis in cancer by releasing
proteases and entrapping circulating tumor cells58. To further substantiate these claims,
we observed an increase in NET formation in our KC mouse model Pdx1-cre;LSLKras(G12D) (Fig 2.10) as the disease progressed and also observed a decrease in NET
formation in our CXCR2+/- Cre-LSL-KrasG12D murine model (Fig 2.11). Although these
results may merely reflect the neutrophil infiltration observed in our previous assays, we
also found that neutrophils conditioned with tumor cell supernatant displayed a propensity
towards NETosis (Fig 2.12). Coincidentally, tumor-expressed G-CSF was determined to
be an inducer of NETosis in tumor-associated neutrophils82. This could potentially explain
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why we observed an increase in NET formation in our experiments. However, the clinical
relevance of NETosis in cancer progression is a relatively unexplored area, particularly in
the context of tumor proliferation and survival. Still, much work needs to be done in this
field.
We also investigated multiple secretory factors released by neutrophils when
conditioned with tumor cell supernatant. Surprisingly, our undifferentiated HL-60
neutrophils downregulated CXCL1 and TGFB expression (Fig 2.6). CXCL1 is an
important chemokine belonging to the CXC chemokine family and is primarily involved in
neutrophil chemotaxis. A mounting pile of evidence suggests that tumor cell-derived
TGFB polarizes tumor-associated neutrophils towards the N2 state. Primarily, these
studies reported attenuation of tumor development following TGFB blockade in various
models67. However, the effect of neutrophil-derived TGFB in cancer has been poorly
documented. Previous reports suggest that TGFB expression stimulates neutrophil
chemotaxis and can thus theoretically explain why we also observe a decrease in CXCL1
expression in tandem with TGFB expression83. Moreover, these results indicate the ability
of neutrophils to become anti-tumorigenic when exposed to tumor cell supernatant.
Our differentiated HL-60 neutrophils showed no significant changes in any cytokine
expression when treated with tumor cell-derived supernatant (Fig 2.7). Our differentiated
HL-60 neutrophils displayed increased expression of CXCL8, IL23, and CXCL2 when
treated with either serum-media or tumor cell supernatant relative to undifferentiated HL60 neutrophils (Fig 2.8,2.9). Many reports suggest differentiated HL-60 neutrophils
possess chemotactic ability compared to undifferentiated HL-60 cells through the
upregulation of integrins such as MAC-1 (CD11b-CD18)84. These integrins bind to ICAM
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molecules on the endothelial cells, permitting neutrophil extravasation in the body. In line
with these observations, CXCL2, another member of the CXC chemokine family, widely
influences neutrophil chemotaxis in tumors. CXCL8, previously called neutrophilactivating peptide 1, is a neutrophil chemotactic factor and can regulate angiogenesis and
metastasis in the TME. Il23 is another pro-inflammatory cytokine involved in T helper 17
cell regulation and function. A major drawback of these assays is that HL-60 cells are not
classified as a true neutrophil cell line. They were derived from circulating leukocytes in
36-year-old women with acute promyelocytic leukemia105. Thus, they may not accurately
represent live neutrophils in the TME of PDAC. However, because of the short lifespan
of live neutrophils, the HL-60 cells proliferative ability makes them an ideal neutrophil
model in our assays.
Interestingly, it was recently discovered that IL23 contributes towards neutrophil
chemotaxis in mice during the bacterial colon infection Clostridium difficile colitis85. Taken
together, upregulation of chemotactic factors CXCL8, IL23, and CXCL2 in our
experiments display the propensity of our differentiated HL60 cells towards chemotaxis
compared to undifferentiated HL60 cells. To our surprise, we observed a decrease in
iNOS expression in our differentiated HL-60 cells. Nitric oxide (NO), produced by
inducible nitric oxide synthase (iNOS), is cytotoxic in large concentrations, and INOS is
usually downregulated in tumor-associated neutrophils86. It is also known that iNOS
expression is increased in differentiated neutrophils in an inflammatory environment 87.
However, similar to our result, Kawase et al. 88 discovered that HL-60 cells differentiated
via DMSO alone were insufficient to induce iNOS expression in these cells.
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CONCLUSION
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Taken together, our results examined the intertwined roles of neutrophils and
tumor cells in the TME of PDAC. Increased recruitment of neutrophils and their byproduct, NETs, were observed as PDAC progressed. This is due to increased expression
of CXCL2 ligands and increased neutrophil survival.
Previous reports suggest that neutrophil incidence in the TME becomes
widespread as the tumor develops, often leading to poor prognosis in most cancer
subtypes. These neutrophils seem to play a distinct role in tumorigenesis and by no
means are just by-products of inflammation in the body. Indeed, the neutrophils in our
assays were able to stimulate tumor cell survival in vitro, hinting that neutrophils might
play a pro-tumorigenic role in PDAC.
The increased propensity of neutrophils in our experiments to undergo NETosis
highlights the ability of neutrophils to persist in the TME even past death, further inhibiting
the body's response against the tumor. However, it still cannot be concluded that
neutrophils play a pro-tumorigenic role in cancer. Many studies have reported that various
neutrophil subtypes often lead to an anti-tumorigenic attack in the TME104. In line with
this, our neutrophils showed a decrease in expression of pro-tumorigenic factors when
treated with tumor cell supernatant.
We also determined that the differentiation of neutrophils led to an upregulation of
multiple chemotactic factors, hinting that neutrophil differentiation in the TME plays a
major role in the recruitment of neutrophils from the bone marrow. Overall, our studies
attempt to highlight the complexity between neutrophil and tumor interaction in PDAC.
They can process both pro and anti-tumorigenic properties. Neutrophil influence in
cancer is still a relatively new concept, and extensive work needs to be done in this field.
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Nevertheless, we hope neutrophils can become a viable therapeutic target in the future
for cancer.

FUTURE DIRECTIONS
There are still many unanswered questions in our work that will be addressed in
the future.
Expression of G-CSF and GMCSF in the TME
We theorized that one of the major reasons we observed increased neutrophil
survival in our mouse models and in vitro assays was the expression of neutrophil growth
factors G-CSF and GM-CSF in the TME. Future studies can prove this theory by staining
these growth factors on our tissue sections or measuring their concentrations in tumor
supernatant via ELISA.
The N1/N2 Polarization
Neutrophil function in the TME is well documented to carry both a pro-tumorigenic
(N2) and an anti-tumorigenic (N1) role. It would be interesting to identify what phenotype
we come across in our in vitro assays. However, the lack of specific surface markers
between the N1/N2 phenotype remains to be a challenging aspect in this regard.
Influencing this polarization towards the N1 state might lead to an effective therapeutic
response. This may be achieved through either TGFB blockade or IFN upregulation in
the TME.
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